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Introduction Clinical Presentation A Rare and Underdiagnosed Form of Pulmonary Hypertension Treatment References
• A mean pulmonary artery pressure 
greater than 25 mm Hg is defined as 
pulmonary hypertension (PH) while 
“chronic thromboembolic pulmonary 
hypertension (CTEPH) is defined as 
pulmonary hypertension in the 
presence of an organized thrombus 
within the pulmonary vascular bed 
that persists at least 3 months after 
the onset of anticoagulant therapy” 
(Gopalan et al., 2016, p. 222). 
• CTEPH is “classified within Group 4 
PH, which is characterized 
pathologically by organized 
thromboembolic material and by 
altered vascular remodeling initiated 
or potentiated by a combination of 
defective angiogenesis, impaired 
fibrinolysis and endothelial 
dysfunction” (Sumimoto et al., 2020, 
p. 1053
• While necessary, it is not enough to 
have persistent perfusion defect to 
develop CTEPH “Approximately 30% 
of patients have persistent defects 
after 6 months of anticoagulation, 
but only 10% of those with 
persistent defects subsequently 
develop CTEPH” (Fernandes et al., 
2016, p. 207). 
• Roughly 0.4 to 9.1% of patients who 
have acute pulmonary emboli (PE) 
develop CTEPH and “long-term 
prognosis is associated with 
significant mortality. Patients with 
CTEPH experience debilitating 
symptoms that have a negative 
impact on their quality of life in 
terms of physical capability, 
psychological wellbeing, and social 
relationships” (Kamenskaya et al., 
2017, p. 747)
• “Because PH is uncommon and there 
is limited awareness, most patients 
receive the diagnosis late in the 
disease course, which results in 
delayed initiation of effective 
therapies, greater patient suffering 
and potentially worse long-term 
clinical outcomes, including survival” 
(Hambly et al., 2016, p. 804). 
• Because of the negative impact  
CTEPH has on the pulmonary and 
cardiac systems, understanding the 
pathophysiology behind the disease 
process is a clinically relevant and 
significant to the profession of Nurse 
Anesthetists.  
Signs and Symptoms
• Signs and symptoms are minimal early 
in the course of the disease
• Exertional dyspnea and unexplained 
exercise intolerance 
• Atypical chest pain, nonproductive 
cough and episodic hemoptysis are 
observed less frequently
• More progressive CTEPH will present 
similar to right ventricular heart failure. 
• Symptoms would include: 
o Tricuspid regurgitant murmur
o S4 cardiac gallop and a right 
ventricular S3
o Pronounced pulmonic component 
of the second heart sound
o Peripheral edema
o Hepatic congestion and pulsatility
and ascites
o Jugular Venous distention
o Cyanosis (Gopalan et al., 2016) 
o Patients re at a higher risk for 
developing right ventricular 
dysfunction and death (Sumimoto
et al., 2020) 
Risk Factors
Diagnosis
Figure 2: A diagnostic algorithm 
developed by UCSD Health, the 
leading medical center in advancing 
the treatment of CTEPH patients 
(Mahmud et al., 2018).
Underlying and Significance of 
Pathophysiology
• In almost 25% of CTEPH patients there was no prior documented history of 
acute PE and 44% did not have a prior history of a deep venous thrombosis 
(DVT) (Gopalan et al., 2016). 
• There are still many uncertainties surrounding the pathophysiology and 
epidemiology of CTEPH. Questions remain concerning what how genetics 
and environmental exposures contribute to the development of the 
disease process (Auger et al.).
• CTEPH is a form of pre-capillary pulmonary hypertension. 
• The unresolved PE transforms into chronic, fibrotic, flow-limiting thrombus 
in the presence of persistent perfusion defects. These vascular scars 
compromise the pulmonary arterial bed leading to pulmonary 
hypertension (Fernandes et al., 2016).
• CTEPH is a dual vascular disorder with stenosis webs, and occlusions found 
primarily at the sites of previous PE in the large and medium pulmonary 
arteries. In the low-resistance vessels a secondary vasculopathy resembling 
other forms of PH is found. Through the progression of the disease, 
anastomosis of bronchial artery branches and precapillary pulmonary 
arterioles occurs. Venous remodeling arise is areas where vascular 
connections between bronchial arteries and pulmonary veins are formed 
(Lang et al. 2016).
• Sustained PH will cause unsustainable strain on the right ventricle (RV) 
leading to cor pulmonale. The elevated pulmonary artery pressures 
increase the workload of the RV, causing hypertrophy. Hypertrophy 
obstructs coronary perfusion leading to ischemia, decreased contractility, 
and increased RV overload (Mccance & Huether, 2019).
Figure 3 Chest radiograph of a 40-year-old female with chronic thromboembolic 
pulmonary hypertension. There is mild cardiomegaly with asymmetric 
enlargement of the proximal pulmonary arteries (star). Note the multifocal 
atelectatic bands (thing arrows) in the right lung and a cavitating infarct (thick 
arrows) in the left lung (Gopalan et al., 2016, p. 223).
Pulmonary Thromboendarterectomy
• “Pulmonary thromboendarterectomy (PTE) is a surgical 
procedure that removes the obstructing thromboembolic 
material, resulting in significant improvement and, in 
many cases, the normalization of pulmonary artery 
pressure and right ventricular function, and thus 
improved survival and quality of life as compared with 
inoperable patients” (Kamenskaya et al., 2017, pp. 747–
748)
• PTE is the most effective treatment for CTEPH with 
mortality rates reduced from 20% to <5% in experienced 
centers (Stanzel et al., 2018)
• Reperfusion injury is the most common injury and cause 
of morbidity and mortality, occurring in 10-40% of PTE 
patients postoperatively (Buchart et al., 2019).
Balloon Pulmonary Angioplasty
• Balloon pulmonary angioplasty (BPA) is a treatment 
option for patients deemed inoperable or with persistent 
PH post PTE (Sumimoto et al., 2020).
• There are currently no standard qualifications to 
determine if a patient is inoperable and is highly 
dependent upon the expertise of the medical team 
assessing the patient (Mahmud et al., 2018)
Medical Management
• Medical management for CTEPH patients includes 
anticoagulants, diuretics, and oxygen for patients in heart 
failure (Pepke-Zaba et al., 2016)
• PH-targeted therapy is appropriate for
o Inoperable distal CTEPH
o Residual CTEPH post-PTE
o Inoperable CTEPH due to comorbidities or refused 
by patient
o Bridge therapy to PTE in hemodynamically unstable 
patients (Pepke-Zaba et al., 2016)
Nursing Implications
• Because of the rarity of the condition, CTEPH is often 
underdiagnosed, or not diagnosed until the disease 
process has progressed into right ventricular heart 
failure. Permeant RV dysfunction and impairment is 
associated with a poor prognosis and high mortality 
(Roller et al., 2018). 
• As the anatomy of the pulmonary vascular bed is altered, 
changes in anatomy and physiological processes in the 
heart and lungs occur. Anesthesia providers administer 
medications that can impair compensatory mechanisms. 
It is imperative to understand the implications of these 
changes and how CTEPH patients differ from other 
patients. 
• Management of CTEPH patients presents many clinical 
complications for anesthesia providers as it impairs both 
respiratory and cardiac systems, so it is imperative that 
anesthesia providers “are well equipped to manage 
patients for surgeries with their potential complications” 
(Chen et al., 2019, p. 169).  
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